Each one of us together for patients

We believe our modular approach to selecting our in vivo and ex vivo programs position us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.